Test Price
2,800 AED✅ Home Collection Available
CLN6 Gene Neuronal Ceroid Lipofuscinosis Type 6 (NCL6) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – Next‑Generation Sequencing (NGS) processed under ISO 9001:2015 accredited protocols for detection of single nucleotide variants, small insertions/deletions, and copy number variants across all coding exons.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM. No fasting required.
- Clinical Guidance: DHA‑licensed Consultant Medical Genetics provides telephonic post‑test correlation, pedigree analysis, and genetic counselling.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This CLN6 gene next‑generation sequencing test detects pathogenic variants in the CLN6 gene responsible for neuronal ceroid lipofuscinosis type 6, a rare, inherited neurodegenerative lysosomal storage disorder. It enables early molecular diagnosis, carrier detection, and informed prenatal planning for at‑risk families. Pre‑test genetic counselling with a three‑generation pedigree chart is mandatory prior to sample collection. Accepted specimen types include whole blood (EDTA), extracted DNA, or FTA card blood spot.
| Feature | DNA Labs UAE ISO‑Accredited NGS Test | Closest Alternative (Single‑Gene Sanger Sequencing) |
|---|---|---|
| Precision / Sensitivity | ≥99.9% detection of SNVs, indels, and CNVs across all coding exons ±10 bp flanking regions | ~95% for point mutations only; limited indel/CNV resolution |
| Methodology | Next‑Generation Sequencing (NGS) with bioinformatic confirmation and Sanger validation of variants | Conventional Sanger sequencing (exon‑by‑exon), lower throughput |
| Turnaround Time | 3 to 4 Weeks | 5 to 7 Weeks |
| Clinical Reporting | DHA‑compliant with ICD‑10 E75.4, LOINC 72498‑6, and genetic counselling integration | Basic variant report without counselling support |
| UAE Regulatory Adherence | Federal Decree‑Law No. 45 of 2021 (PDPL), Federal Law No. 2 of 2019 (Health ICT), and DHA guidelines | Often lacks local statutory safeguards |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh – Consultant Medical Genetics (DHA Registration ID: 9294403):
“As a Consultant in Medical Genetics, I emphasize that identification of a pathogenic CLN6 variant requires careful correlation with clinical presentation, family pedigree analysis, and, where indicated, enzyme assays or neuroimaging. A negative sequencing result does not entirely rule out deep intronic or structural variants. Comprehensive pre‑ and post‑test genetic counselling is essential to interpret results accurately within the broader clinical context.”
Clinical Decision Advisory
Genetic test results provide diagnostic information but should never replace a comprehensive clinical evaluation by a neurologist or genetic specialist. Treatment decisions, including any adjustments to prescribed therapy, must be made in consultation with your healthcare team. Do not discontinue or alter medications based solely on genetic findings.
Safety & Exclusion Criteria
- Exclusion Criteria: This test is not suitable for individuals who have undergone allogeneic bone marrow transplant or where somatic mosaicism for CLN6 is suspected. For paediatric patients, mandatory pre‑test genetic counselling and written guardian consent are required in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Emergency Indicators: This test does not cause acute symptoms. However, new‑onset seizures, rapid vision deterioration, or developmental regression may indicate disease progression and warrant immediate medical attention.
Patient FAQ & Clinical Guidance
1. What is the CLN6 gene genetic test and why is it important?
This next‑generation sequencing test analyzes the entire CLN6 gene for pathogenic mutations causing neuronal ceroid lipofuscinosis type 6, a rare progressive neurodegenerative disorder. It enables early molecular diagnosis, accurate carrier identification, and informed reproductive planning for families at risk.
2. How is the home blood collection performed and what preparation is needed?
A DHA‑licensed phlebotomist performs a venipuncture at your residence between 8 AM and 11 PM using temperature‑controlled cold‑chain logistics. No fasting is required; only a brief medical history and pre‑test genetic counselling session are needed prior to collection.
3. Can the test be performed for children and what are the implications of results?
Yes, the test is available for paediatric patients with mandatory pre‑test genetic counselling and written guardian consent as required by UAE medical liability law. Results can identify affected children and silent carriers, providing a foundation for early intervention, family planning, and multidisciplinary care coordination.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and processed exclusively within DHA‑licensed facilities. Patient consent, data minimization, and purpose limitation principles govern every stage of the testing lifecycle. No genetic information is shared with third parties without explicit written authorization.
The laboratory adheres to DHA standards for clinical genetic testing, including mandatory pre‑ and post‑test genetic counselling, and maintains ISO 9001:2015 quality management certification.
Clinical & Logistical Metadata
| Test Name | CLN6 Gene Neuronal Ceroid Lipofuscinosis Type 6 (NCL6) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card Blood Spot |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | E75.4 |
| LOINC Code | 72498-6 |
| DHA Facility License & Laboratory Address Invariants | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians